2024 - Cancer Currents Blog
-
A 10-year-old program at an NCI-Designated Cancer Center has had substantial success at increasing the number of adolescents and young adults with cancer who get recommended treatment and services, including greater clinical trial participation and use of fertility services.
-
In a clinical trial, people with advanced cancer and cachexia treated with the experimental drug ponsegromab gained an average of 2 to 6 pounds over 12 weeks, depending on the dose they received. Participants treated with the placebo lost an average of 1 pound over the same time period.
-
Up to 40% of people being treated for cancer use cannabis to help with side effects like pain and anxiety. But with evidence from studies on cannabis lacking, clinicians feel ill-equipped to answer patient questions about its safety and effectiveness.
-
FDA recently approved the Shield test, the first blood test for the primary screening of people at average risk of colorectal cancer. Where does it fit in with other screening options for the disease, including colonoscopy and stool tests?
-
Some women who receive a false-positive result on a mammogram may not come back for routine breast cancer screening in the future, a new study finds. Better doctor–patient communication about the screening process is needed, several researchers said.
-
Results from a French clinical trial have identified what experts say should now be the recommended initial treatment of advanced leiomyosarcoma. In the trial, the combination of trabectedin (Yondelis) and doxorubicin improved survival by a median of 9 months.
-
Osteonecrosis of the jaw was thought to be a rare side effect of drugs like denosumab (Xgeva) that lessen bone problems when cancer has spread to the bone. But a new study has found that the painful side effect is more common than once thought.
-
A new study may provide important new insights into breast cancer metastasis. Blood vessels within tumors release a molecule that draws sensory nerves closer to the tumors, the study shows. This close proximity turns on genes in the cancer cells that drive metastasis.
-
Trial participants who stopped imatinib had a more rapid worsening of disease, a shorter time until resistance, and did not live as long as participants who continued the therapy uninterrupted.
-
Researchers have identified hundreds of promising targets for existing drugs or potential new cancer drugs. The findings relied heavily on proteogenomic data from more than 1,000 tumors representing 10 types of cancer released last year by NCI's CPTAC program.